Teleflex Incorporated announced the results of a pre-clinical intravascular study, highlighting Arrow® PICC with Chlorag+ard® Technology and its ability to significantly reduce thrombus formation when compared to competitive non-eluting antithrombogenic technologies. The pre-clinical study titled ‘Catheter Technologies: Is eluting technology or non-eluting technology more effective in preventing thrombus accumulation" by Kamna Giare-Patel, MS, et al, evaluated the effectiveness of three types of peripherally inserted central venous catheters (PICCs) with antithrombogenic properties as compared to uncoated PICCs in a clinically simulated ovine model. The three test groups consisted of PICCs with fluorine-based technology (AngioDynamics® BioFlo™ PICC with Endexo™ Technology), chlorhexidine-based technology (Arrow® PICC with Chlorag+ard® Technology) and Amphiphilic PMEA based technology (Terumo® Xcoating™).

After 30 days, all catheters were explanted by dissecting the vessels open. The amount of accumulated thrombus on the catheter surfaces was measured for thrombus weight and length. Arrow® PICC with Chlorag+ard® Technology showed the least amount of thrombus as a result of greatest weight reduction (81%) and length reduction (76%) when compared to the uncoated control catheter.